Nanotechnology
Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
Published in Drug Law Weekly, May 1st, 2007
Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, announced results from two pre-clinical studies that support the role of SPARC (secreted protein acidic and rich in cysteine) expression in cancer and Abraxis' nanoparticle albumin-bound (nab(TM)) tumor-targeting technology at the 98th American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2007 in Los Angeles.
"Both pre-clinical studies evaluating the role of SPARC expression provide strong evidence in support of the mechanism of action for our nab-technology therapeutic candidates," said Neil P. Desai, Ph.D., vice president of research and development at...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-05-01)
More Articles from Drug Law Weekly
- Cancer
Eisai Announces Completion of Acquisition of Morphotek - Clinical Trial Research
Cell Genesys Announces Registered Direct Common Stock and Warrant Offering of $60 Million - Drug Safety
Poll: Consumers Say Government Failed to Protect them from Dangerous Prescription Drugs; Americans Back Host of Drug Safety Reforms - Financing
CytRx Enters into Agreements for $37.0 Million Private Placement - Lerach Coughlin Stoia Geller Rudman & Robbins LLP
Lerach Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against Amgen Inc. - Medicare and Medicaid
Cell Therapeutics, Inc. to Pay United States $10.5 Million to Resolve Claims for Illegal Marketing of Cancer Drug - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
